Literature summary for 3.4.14.5 extracted from

Augstein, P.; Berg, S.; Heinke, P.; Altmann, S.; Salzsieder, E.; Demuth, H.U.; Freyse, E.J.
Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance (2008), Diabetes Obes. Metab., 10, 850-861.

Search for more literature for 3.4.14.5

Inhibitors

Inhibitors	Comment	Organism	Structure
isoleucine thiazolidide	i.e. P32/98. Enhancement of incretin with the DPP-4 inhibitor P32/98 has therapeutic effects in hyperinsulinaemia, hyperglycaemia and impaired glucose toleranceIGT in Zucker rats with incipient impaired glucose tolerance and manifest impaired glucose tolerance. Apparently, administration of P32/98 in Zucker rats with incipient impaired glucose tolerance results in more efficient beta-cell function, which is associated with less need for insulin to cope with deterioration of glucose tolerance. P32/98 has a strong effect on dyslipidaemia in manifest impaired glucose tolerance. P32/98 has no side effect on intestinal growth. Daily intake of P32/98 is a promising strategy for treatment of glucose intolerance and has the potential to prevent type 2 diabetes	Rattus norvegicus

Organism

Organism	UniProt	Comment	Textmining
Rattus norvegicus	-	Zucker rats	-

Synonyms

Synonyms	Comment	Organism
DPP-4	-	Rattus norvegicus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)